Physician profile
Kendra Wiley
NPI 1205347549
$1,807.51
in general payments reported to CMS, 2019-2025
11 companies · $1,498 in 2025
The $1,498 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $163 · 2022: $48.73 · 2024: $97.92 · 2025: $1,498.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,191 · Food and Beverage: $405.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,190.72 |
| Food and Beverage | $405.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Si-Bone, INC. | $1,353.55 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $115.58 | 2021 | |
| Stryker Corporation | $58.24 | 2024 | Alphavent |
| Vertex Pharmaceuticals Incorporated | $52.82 | 2025 | |
| Bioventus LLC | $48.73 | 2022 | |
| Organogenesis INC. | $47.58 | 2024-2025 | Puraply Wound Matrix, Puraply Franchise |
| Solventum Corporation | $47.24 | 2025 | V.A.C. Granufoam, Prevena |
| Smith+Nephew, INC. | $33.94 | 2021-2025 | Pico 7 |
| Amgen INC. | $18.27 | 2021 | |
| Kerecis Limited | $16.83 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Pacira Therapeutics, INC. | $14.73 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kendra Wiley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.